Deciphera rakes in over $90 mln

By Iris Dorbian — 1 month ago

Waltham, Massachusetts-based Deciphera Pharmaceuticals, an biotechnology company focused on developing advanced kinase inhibitor treatments, has raised over $90 million in Series B funding. The company’s newest investor is SV Life Sciences. In addition to the investment, Dr. Michael Ross, a managing partner at SV Life Sciences, has been added to Deciphera’s board of directors.

Continue

DDF launches $100 mln fund focused on treating dementia

By Iris Dorbian — 4 months ago

The Dementia Discovery Fund, which focuses on developing new dementia treatments, has raised $100 million. DDF’s backers include UK Government’s Department of Health, Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda. SV Life Sciences is managing the fund.

Continue

Allergan to buy VC-backed AqueSys for $300 mln

By Iris Dorbian — 5 months ago

Allergan plc has agreed to acquire Aliso Viejo, California-based medical device company AqueSys for $300 million upfront in cash. The deal is expected to close in the fourth quarter of this year. AqueSys’ backers include Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences.

Continue

ReShape Medical racks up $38 mln

By Iris Dorbian — 5 months ago

San Clemente, California-based ReShape Medical, a weight loss-focused medical device company, has closed $38 million in Series D funding. HealthCor Partners Management LP led the round with participation from Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors.

Continue

Ximedica buys Bridge Design

By Luisa Beltran — 6 months ago

Ximedica, an SV Life Sciences portfolio company, said Tuesday it has acquired Bridge Design. Financial terms weren’t announced. San Francisco-based Bridge Design provides design services for physical and digital products, including mHealth.

Continue

Biotech company Avitide pulls in Series C funds

By Iris Dorbian — 6 months ago

Lebanon, New Hampshire-based biotech company Avitide Inc has secured an undisclosed amount of Series C funding. NeoMed Management led the round with participation from previous backers Polaris Partners, OrbiMed Advisors, SV Life Sciences and Borealis Ventures. In addition to the funding, Claudio Nessi of NeoMed has been added to Avitide’s board of directors.

Continue

EBR Systems nets $20 mln

By Iris Dorbian — 10 months ago

Sunnyvale, California-based EBR Systems Inc, a wireless cardiac pacing system provider for heart failure, has secured $20 million in funding. Emergent Medical Partners led the round with participation from other investors that include Split Rock Partners, SV Life Sciences, Delphi Ventures and St. Paul Venture Capital. According to the company, the capital infusion will be used for clinical studies and regulatory filings.

Continue

VC-backed Entellus Medical sets IPO pricing terms

By Iris Dorbian — 1 year ago

According to an amended SEC filing, Entellus Medical is planning on selling 4.375 million shares of its IPO at a price range between $15 and $17 per share. BofA Merrill Lynch and Piper Jaffray are serving as lead underwriters. Entellus will list the IPO on the NASDAQ under the ticker symbol “ENTL.” Based in Plymouth, Minnesota , Entellus Media provides treatment solutions for chronic sinusitis. Its backers include Covidien Ventures, SV Life Sciences, Essex Wodlands, Split Rock Partners and Greenspring Associates.

 

Continue

Merck acquires VC-backed OncoEthix

By Iris Dorbian — 1 year ago

Merck has bought Swiss-based OncoEthix, a biotech firm that focuses on developing cancer drugs. The acquisition is being made with an upfront payment of up to $110 million. OncoEthix’s backers included Index Ventures, SV Life Sciences, Endeavour Vision and Edmond de Rothschild Investment Partners.

Continue

CardioKinetix racks up $50 mln

By Iris Dorbian — 1 year ago

CardioKinetix, a Menlo Park, Calif.-based medical device firm, has received $50 million in funding. Edwards Lifesciences Corp. led the round with participation from return backers U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity. CardioKinetix has also inked an agreement with Edwards Lifesciences Corp. that gives the latter company the option to acquire CardioKinetix “based on future regulatory milestones.”

Continue

SV Life Sciences backs Direct Flow Medical

By Iris Dorbian — 1 year ago

Direct Flow Medical has raised $32 million in funding in a round led by SV Life Sciences. Also, the firm has hired Chris Richardson as its first chief commercial officer. Based in Santa Rosa, Calif., Direct Flow Medical is a provider of transcatheter technologies that treat heart disease.

Continue

SV Life Sciences acquires majority stake in Ximedica

By Iris Dorbian — 1 year ago

SV Life Sciences has bought a majority stake in Ximedica. No financial terms were disclosed. As a result of the transaction, Randall S. Barko, president and CEO of Ximedica and the company’s current management will remain. Also, Paul LaViolette, managing partner and COO at SV Life Sciences, has been named chairman of Ximedica’s board. Headquartered in Providence, RI, Ximedica is a medical tech firm.

Continue

Bicycle Therapeutics reels in $32 mln

By Iris Dorbian — 1 year ago

Bicycle Therapeutics has raised $32 million in funding. Previous backers Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management all participated in the round. Based in Cambridge, UK, Bicycle Therapeutics is a biotech firm focused on developing bicyclic peptides.

Continue

SV Life Sciences expands team with new hires

By Iris Dorbian — 2 years ago

SV Life Sciences has hired Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners. Burgess was the founder, president and CEO of Rempex Pharmaceuticals while Mascioli was the CEO of Affinium Pharmaceuticals. And, previously, Mendelsohn worked at Merck Research Laboratories where he served as senior vice president and global franchise head, cardiovascular diseases.

Continue

PanOptica snags $45 mln Series B funds

By Iris Dorbian — 2 years ago

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

Continue